Precision medicine in sepsis: lessons from the TIGRIS trial and the reawakening of targeted therapy
Toshiaki Iba, Julie Helms, Hideshi Okada, Kunihiko Nagakari, Ricard Ferrer · 2026
Read Precision medicine in sepsis: lessons from the TIGRIS trial and the reawakening of targeted therapy by Toshiaki Iba, Julie Helms, Hideshi Okada, Kunihiko Nagakari, Ricard Ferrer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13285492.txt.
Description
Sepsis kills in part because it is not one ill but many wearing one name. Toshiaki Iba and four co-authors argue in 2026 that decades of failed drug trials share one flaw: they signed up all comers, mixing biologies that no one drug could fit. A poison from germ walls drives much of the harm, and a bedside test can now read its level live in each patient. Levels swing wide between folk and shift by the hour.
One blood-washing cure flopped in broad trials yet may work in the right slice of folk. A new trial picked its folk by the poison test plus an organ-fail score, marking a window where the poison is both real and reachable. Early signs favor the cure in that window. The team read the trial as a template for sepsis care tuned to each body.
Catalog record
| CREATOR | Toshiaki Iba, Julie Helms, Hideshi Okada, Kunihiko Nagakari, Ricard Ferrer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |